Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 7/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280318 | 0.88 | SMN1; SMN2 (0.55) | GAASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6284717 | 0.87 | KDM4E (0.57) | GAASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL1520344 | 0.86 | SMN1; SMN2 (0.71) | GAASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6964163 | 0.85 | ALDH1A1 (0.54) | GAASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL29355435 | 0.85 | ALDH1A1 (0.54) | GAASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL17186221 | 0.84 | SMN1; SMN2 (0.61) | GAASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6958741 | 0.84 | LMNA (0.62) | GAASMN1; SMN2ALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL17186439 | 0.83 | SMN1; SMN2 (0.60) | GAASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6958155 | 0.81 | KDM4E (0.49) | GAASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6953393 | 0.81 | SMN1; SMN2 (0.52) | GAASMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117343266-A | Polyurethane heat-insulating material for air film reinforced concrete dome structure | 烟台市顺达聚氨酯有限责任公司 | 2024-01-05 | — | — | CN | claimed |
| CN-113469888-B | Method and device for correcting inclination angle of circular electronic seal | 江西金格科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| EP-4635569-A2 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | Peptron, Inc. (KR) | 2025-10-22 | — | — | EP | disclosed |
| US-20250295587-A1 | COMPLEX LIPID NANOPARTICLES ENCAPSULATING POLYPEPTIDES AND USES THEREOF | SAIL BIOMEDICINES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20240398884-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240252594-A1 | COMBINATION THERAPY FOR NEURODEGENERATIVE DISEASES | ALETA NEUROSCIENCE LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240210846-A1 | IMAGE FORMATION APPARATUS | OKI ELECTRIC INDUSTRY CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE LLC (US) | 2024-02-22 | — | — | US | disclosed |
| CN-117343266-A | Polyurethane heat-insulating material for air film reinforced concrete dome structure | 烟台市顺达聚氨酯有限责任公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20240002258-A1 | WATER RECLAMATION SYSTEM USING OIL AS A HEAT TRANSFER MEDIUM AND LIQUID SALT COLLECTOR | Anderson Erik Andrew (US) | 2024-01-04 | — | — | US | disclosed |
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023042178-A2 | COMBINATION THERAPY FOR NEURODEGENERATIVE DISEASES | ALETA NEUROSCIENCE, LLC (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2022224118-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE, LLC (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20220288150-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-09-15 | — | — | US | disclosed |
| CN-110016479-B | Alfalfa MsGPF gene | 河南省农业科学院畜牧兽医研究所 | 2022-08-26 | — | — | CN | disclosed |
| US-20220265563-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | PEPTRON, INC. (KR) | 2022-08-25 | — | — | US | disclosed |
| CN-112280001-B | High-flame-retardant combined polyether for floor | 绍兴市华创聚氨酯有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20220152139-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-05-19 | — | — | US | disclosed |
| US-11273130-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | The United States, as represented by the Secretary Department of Health and Human Services (US) | 2022-03-15 | — | — | US | disclosed |
| US-11230599-B2 | Tumor mutational load | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265563-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | GLP1R, IAPP, BDNF | GAA 1616/4885SMN1; SMN2 47/4885ALDH1A1 4462/4885 |
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | BAG3, BAG2, PHB1 | GAA 4/4885SMN1; SMN2 751/4885ALDH1A1 1513/4885 |
| US-11273130-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | GLP1R, IAPP, BDNF | GAA 1616/4885SMN1; SMN2 47/4885ALDH1A1 4462/4885 |
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | GLP1R, IAPP, BDNF | GAA 1616/4885SMN1; SMN2 47/4885ALDH1A1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.